A new study has found a surprising link between high levels of methylmalonic acid and the weakening of CD8 + T cells, shedding light on potential pathways through which aging may promote lung cancer progression. Moffitt Cancer Center researchers have found new insights into how metabolic changes associated with aging can impact immune responses against tumors. Their study, published in Oncogene , explores how increased methylmalonic acid impairs the activation and effector functions of CD8 + T cells, immune cells that play a vital role in fighting cancer.
Methylmalonic acid levels are normally low in healthy individuals. Elevated levels have been linked to aging and vitamin B12 deficiency, raising questions about their role in cancer biology. "Our research shows that methylmalonic acid not only increases with age but also makes CD8 + T cells weaker by disrupting their energy production ," said Ana Gomes, Ph.
D., lead author on the study and principal investigator in the Molecular Oncology Department at Moffitt. "This makes it harder for the immune system to fight cancer, suggesting that targeting methylmalonic acid could help improve cancer treatment .
" Researchers found that methylmalonic acid treatment significantly reduced the activity of CD8 + T cells, an important component of the immune response to tumors. The study's results indicate that methylmalonic acid influences global gene expression in these cells, leading to the downregulation of key pathways involved in immune.